Transplantation

A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.

Transplantation

Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA

A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.

Transplantation

Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA

Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.

Transplantation

Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA

Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.

Transplantation

Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA

Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.

Transplantation

Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L

Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

Transplantation

Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA

Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.

Transplantation

Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L

Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

Transplantation

Ellenhorn JD, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA

Pages